The Dutch TIA Trial and a literature review indicate that low-dose aspirin in any daily dose of at least 30 mg up to 325 mg is effective in the prevention of threatened stroke, but 87% of subsequent strokes in patients with TIAs or nondisabling ischemic strokes are not prevented. Anticoagulants have been proven highly efficacious in trials after myocardial infarction and after cerebral ischemia and atria1 fibrillation. In patients after cerebral ischemia of presumed atherosclerotic origin, high-intensity anticoagulation (INR 3.0 to 4.5) is not safe. Data from SPIRIT (Stroke Prevention in Reversible Ischemia Trial) indicate that anticoagulant therapy with an intensity of INR 2.0 to 3.0 is safe in stroke prevention. In the 2nd European Stroke Prevention Trial (ESPS-2) a 22% relative risk reduction of the combination of aspirin and dipyridamole above that of aspirin only is reported; the results of this trial, however, are controversial. ESPRIT is designed to randomize 4500 patients between oral anticoagulation (INR 2.0 to 3.0), the combination of dipyridamole (400 mg daily) plus aspirin (in any dose between 30 and 325 mg) and aspirin only (in any dose between 30 and 325 mg). Primary outcome event is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; the outcome assessment will be blinded. ESPRIT is an international, multicenter study in (at least) the following countries: Australia, Austria, Belgium, China, Germany, France, India, Israel, Italy, the Netherlands, Portugal, Singapore, Spain, Sweden, Switzerland, United Kingdom and the United States. Recruitment for this trial started in July 1997; as of July 2005, 3327 patients from 85 hospitals had been included. With 1200 patient-years of follow-up a total of 767 outcome events have been reported, including 38 intracranial bleeds. As the investigators are still blinded, these outcome events are not yet separated per treatment group. However, these data suggest that treatment with oral anticoagulants in the current INR range is safe. New centers are still invited to participate. 
Carotid Occlusion Surgery Study (COSS)
COSS is a randomized, partially blinded, controlled trial to test whether extracranial-intracranial arterial bypass surgery, when added to best medical therapy, can reduce by 40% subsequent ipsilateral ischemic stroke at 2 years in subjects with recently symptomatic internal carotid artery occlusion and ipsilateral increased oxygen extraction fraction measured by positron-emission tomography. PET scans will be performed within 120 days of the qualifying transient ischemic attack or stroke on 930 clinically eligible subjects to identify 372 with increased oxygen extraction fraction distal to an occluded carotid who will be randomized to receive surgery or no surgery. Study participants will be followed up for a minimum of 2 years. Follow-up includes clinic visits at 1 month, 3 months, and every 3 months thereafter. All participants will receive best medical management, which includes management of hypertension and other medical risk factors. 
Carotid Revascularization Endarterectomy versus Stenting Trial (CREST)
CREST is a prospective, randomized, multicenter, clinical trial to assess the relative efficacy of carotid endarterectomy (CEA) versus carotid artery stenting (CAS) using the RX ACCULINK Carotid Stent System and RX ACCUNET Embolic Protection Device in preventing stroke, myocardial infarction and death during the 30-day periprocedural period and ipsilateral stroke thereafter in subjects with symptomatic and asymptomatic extracranial carotid stenosis. The study includes a lead-in phase for credentialing of interventionalists, beyond their initial training and certification requirements. Approximately 2500 subjects with TIA, amaurosis fugax, or nondisabling stroke within 180 days of randomization and ipsilateral carotid stenosis Ն50% (defined as Ն70% by ultrasound or Ն50% by angiography) for symptomatic patients and Ͼ60% (defined as Ͼ70% by ultrasound or Ͼ60% by angiography) for asymptomatic patients will be followed for up to four years. Follow-up includes clinic visits at 1, 6, and 12 months, then every 6 months for study duration with phone contact every 3 months. All patients will receive best medical *Indicates centers that are currently recruiting. management, which includes treatment with aspirin, management of hypertension and medical risk factors.
Recruitment of patients began in December 2000, but the start-up date will vary across centers depending upon their completion of certification and regulatory requirements. Currently 1270 lead-in participants and 611 randomized subjects have been enrolled. 
*Clots in Legs or TEDS after Stroke (CLOTS Trial)
This is a randomized trial to establish the effectiveness of graduated compression stockings to prevent poststroke deep-vein thrombosis (DVT). The CLOTS Trial is a family of 2 multicenter, international, partially blinded, randomized controlled trials that aim to establish the effectiveness of graduated compression stockings (GCS) to prevent poststroke DVT. Trial 1 will compare full-length GCS with no GCS, and trial 2 will compare full-length GCS with below-knee GCS. Centers will randomize consenting patients into either trial 1 or 2, depending on their current practice and beliefs with respect to GCS after stroke. Patients who are admitted to hospital within 1 week of an acute stroke and are immobile can be randomized into CLOTS. The allocated type of GCS is applied to both legs as soon as possible after randomization and worn until the patient is independently mobile around the ward or is discharged from hospital, or until the patient declines to wear them. Patients undergo a routine Doppler ultrasound of both legs at 7 days and, wherever possible, 30 days after randomization. The primary outcomes are the presence of DVT in the popliteal vein or more proximal vein detected on either Doppler ultrasound or venography within 7 and 30 days of randomization. Patients are followed up at 6 months to identify late events, survival, and functional status. Up to 40% of acute stroke patients on hospital admission are already taking antihypertensive therapy, and most will develop elevated blood pressure levels as an acute complication of the stroke. However, no guidelines exist as to whether antihypertensive therapy should be continued or discontinued after acute stroke. The Continue Or Stop postStroke Antihypertensives Collaborative Study (COSSACS) is a multicenter, prospective, randomized, open, blinded-endpoint study to assess whether existing antihypertensive therapy should be continued or discontinued within 48 hours of stroke onset and for the subsequent 2 weeks. A study population of 2900 patients with both cerebral infarction and hemorrhage on antihypertensive treatment at hospital admission will be recruited giving the study a 90% power at the 5% significance level to detect a relative reduction of 10% (absolute risk reduction of 6%) in death and dependency between continuation and discontinuation groups at 2 weeks. Nondysphagic, hospital-admitted stroke patients will be recruited within 48 hours of stroke onset and also within 24 hours of last dose of preexisting antihypertensive therapy. Baseline investigations will include blood pressure measurement using UA-767 monitor, modified Rankin Scale score, Barthel Index, National Institutes of Health Stroke Score, and Oxfordshire Community Stroke Project Classification. Patients will be randomized by secure Web site to continue or discontinue pre-existing antihypertensive treatment for a 2-week period. Blood pressure, modified Rankin Scale score, Barthel Index, and National Institutes of Health Stroke Score will be repeated at 2 weeks by an observer blinded to the randomized group. Mortality and health-related quality of life outcomes will be centrally recorded at 6 months.
The primary outcome will be death or dependency (modified Rankin Scale score Ն3) at 2 weeks after randomization. Early secondary outcomes of neurological deterioration, functional status, blood pressure changes from admission, and discharge destination will be recorded at 2 weeks. Late secondary outcome measures of death and dependency, fatal and nonfatal stroke recurrence, functional status, health-related quality of life, and discharge destination will be recorded at 6 months. 
Controlling Hypertension and Hypotension Immediately PostStroke (CHHIPS) Trial
Following acute stroke up to 60% of patients will be hypertensive (SBP 160 Նmm Hg) and nearly 20% hypotensive (SBP Ͻ140 mm Hg), both high and low values being associated with adverse prognosis in terms of death and disability. Furthermore, the acute management of these poststroke blood pressure changes is a matter of some debate, as reflected in surveys of clinical practice, and there is a lack of evidence-based clinical guidelines to inform the management of this common problem. The Controlling Hypertension and Hypotension Immediately Post-Stroke (CHHIPS) Trial is a United Kingdom multicenter, prospective, randomized, doubleblind, placebo-controlled, titrated-dose trial to assess whether hypertension and hypotension should be therapeutically manipulated following acute stroke. This trial will access depressor therapy using lisinopril and labetalol compared to placebo in both dysphagic (sublingual and intravenous administration routes) and nondysphagic (oral route) hypertensive (SBP 160 Նmm Hg) ischemic and hemorrhagic stroke patients recruited within 36 hours of stroke onset. Dose titrations will be made at 4 and 8 hours postrandomization with the aim of achieving target SBP (150 mm Hg [range, 145 to 155 mm Hg] or a 15 mm Hg reduction from baseline), and treatment will be continued until 2 weeks following stroke. A population of 1650 hypertensive patients will give the study an 80% power at the 5% significance level to detect a relative reduction of 15% in death and dependency between either of the 2 treatment groups and placebo.
*Indicates centers that are currently recruiting. Also, hypotensive (SBP Ͻ140 mm Hg) patients will be recruited within 12 hours of neuroradiologically confirmed nonhemorrhagic stroke, and receive intravenous phenylephrine or placebo infusion to achieve target SBP (150 mm Hg [range, 145 to 155 mm Hg] or a 15 mm Hg rise from baseline). Pressor treatment will be continued for a 24-hour period only. A population of 400 hypotensive patients will give the study an 80% power at the 5% significance level to detect a relative reduction of 25% in death and dependency between active treatment and placebo groups. The primary outcome measure will be death and dependency at 2 weeks poststroke, and secondary neurological, disability, and health-related quality-of-life outcomes will be collected at 2 weeks and 3 months. To compare the efficacy of decompressive surgery in addition to conservative treatment to reduce mortality and to improve functional outcome after malignant hemispheric ischemic cerebral infarction with space-occupying edema with conservative treatment alone. Primary endpoints: mortality after 30 days, functional outcome (mRS, dichotomized at Ϸ3) after 6 months. Secondary endpoints: mortality after 30 days and 6 months, functional outcome after 12 months, complications related to surgery, infarct size. Prospective, randomized, open, controlled, multicenter study.
Posttreatment observation phase: 1 year. Patients with spaceoccupying infarction of the middle cerebral artery aged 18 to 60 years with an onset of symptoms before 12 and less than 36 hours previous to randomization.
Sequential statistical analysis: the study will be interrupted when mortality at 30 days has reached statistically significant difference. After blinded analysis of primary outcome recalculation of sample size. Patients will be randomized to either conversation full-scale ICU treatment or decompressive surgery plus ICU treatment. After randomization treatment is started immediately. Principal Investigator: Prof Dr Werner Hacke, Prof Dr Peter Schmiedek, Prof Dr Stefan Schwab, University of Heidelberg Location: Coordinating center, Department of Neurology, University of Heidelberg. Phone 49-6221-568210. Fax 49-6221-565348. E-mail neurology@med.uni-heidelberg.de Number of Centers: German multicenter study. Ten centers are active. Sponsor: Investigator Dates of Study: Patient recruitment started in January 2004. 14 patients have been randomized and treated. Concerning the total number of patients fulfilling the inclusion criteria for the study in all participating centers, the estimated duration of the study will be 3 years.
*Efficacy of Nitric Oxide in Stroke (ENOS) Trial
Nitric oxide is a multimodal molecule that is a candidate treatment for acute ischemic and hemorrhagic stroke, as based on preclinical and preliminary clinical data. Potential mechanisms of action include lowering blood pressure, improving cerebral perfusion, and neuroprotection. ENOS is a large, international, academic, randomized, collaborative, controlled trial designed to test the safety and efficacy of transdermal glyceryl trinitrate (a nitric oxide donor) in 5000 patients when given within 48 hours of stroke onset. Patients who are taking antihypertensive therapy at the time of their stroke will also be randomized to continue or temporarily stop this therapy. The primary end point is combined death or dependency (modified Rankin Scale score 3 to 6) at 3 months, to be assessed centrally by telephone. Subgroup analyses will include efficacy in patients with ischemic stroke, hypertension (systolic blood pressure Ն160 mm Hg), or treatment within 12 hours. Randomization and data registration are performed over the Internet. Centers are invited to join the collaborative group. 
Evaluation of the STARflex ® Septal Closure System in Patients with a Stroke or Transient Ischemic Attack due to Presumed Paradoxical Embolism through a PFO (CLOSURE)
CLOSURE is a prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the STARflex ® Septal Closure System versus aspirin and/or warfarin therapy for the prevention of stroke, TIA and mortality in patients with an initial stroke or TIA due to a presumed paradoxical embolism through a patent foramen ovale (PFO). The goal is to determine if device closure of a PFO is superior to best medical therapy for preventing recurrent stroke or TIA in patients with an initial cryptogenic stroke/TIA and a PFO. Sixteen hundred patients (800 in each group) at up to 100 sites nationally will be randomized within 180 days of the entry event. Study patients will be followed for 2 years. All strokes and TIAs will be adjudicated by a blinded Clinical Events Committee using prespecified clinical and MR imaging definitions. The primary endpoint of incidence of 24-month stroke or TIA, all cause mortality for the first 30 days of follow up or hospital discharge, whichever is longer, and neurological mortality from Ն31 days of follow up will be analyzed on an intent-to-treat basis using the 2 test and logistic regression adjusting for study center and demographic characteristics deemed related to the primary endpoint. Safety analyses will focus on the incidence of severe adverse events related to either device insertion or major bleeding complications on medical therapy. 
*Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Phase 3 Trial
Magnesium is neuroprotective in preclinical models of stroke and has been safe and shown signals of potential efficacy when administered early after onset in initial human stroke clinical trials. Delayed initiation of neuroprotective agents has hindered past phase 3 neuroprotective agent trials. The purpose of the FAST-MAG phase 3 trial is to demonstrate that paramedic initiation of intravenous magnesium sulfate within 2 hours of symptom onset improves the long-term functional outcome of hyperacute stroke patients.
FAST-MAG is a multicenter, randomized, double-blind, placebocontrolled phase 3 trial that will enroll 1298 patients (649 in each arm). The study population consists of prehospital patients with acute stroke, including both cerebral infarction and intracerebral hemorrhage patients. Inclusion criteria: (1) likely stroke as identified by the Los Angeles Prehospital Stroke Screen (LAPSS), (2) age 40 to 95, (3) symptom onset within 2 hours of treatment initiation, (4) deficit present greater than or equal to 15 minutes. Study agent will be started within 1 hour of onset in 1/2 of enrolled patients and between 1 to 2 hours after onset in the remainder. Study sites are up to 80 ambulance-receiving hospitals in Los Angeles County, serviced by the LA County EMS Agency. In the study intervention, paramedics administer a loading dose of magnesium sulfate (Mg) or matched placebo in the field, 4 grams over 15 minutes. In the ED, a maintenance infusion follows, 16 g Mg or matched placebo over 24 hours. Explicit informed consent is obtained in the field by phone physician contact, either from competent patients or on scene legally authorized representatives, using an in-vehicle FAST-MAG cellular phone.
The primary endpoint is the distribution of scores across all 7 strata of the modified Rankin Scale global measure of functional outcome, assessed 90 days after treatment. Secondary endpoints include NIHSS (neurologic deficit), Barthel Index (disability), and Stroke Impact Scale (quality of life). 
*Global Carotid Artery Stent Registry
This registry is an expanding, multicenter, retrospective study to determine the benefits and risks of percutaneous transluminal angioplasty with stent placement of the cervical carotid arteries in patients with cerebrovascular disease. The basic intent of the survey is to evaluate the growth of carotid stent placement and obtain an early review of its results, including stent procedures, technical success, and types of stents placed. In addition, complications such as transient ischemic attacks, minor and major strokes, and deaths for symptomatic and asymptomatic patients will be studied. Long-term follow-up involving restenosis rates and neurological events will be monitored. The MASH-2 study is a prospective randomized, placebocontrolled, international multicenter trial to determine whether magnesium reduces the frequency of poor outcome (death or dependence) in patients admitted within 4 days after aneurysmal subarachnoid hemorrhage. Magnesium sulfate 64 mmol/d (or placebo) is started intravenously as soon as possible after informed consent and continued until 20 days after the hemorrhage. We plan to include 1200 patients in 5 year. 
Optimising the Analysis of Stroke Trials (OAST)
Most trials in acute stroke have been neutral (or even negative). One possible explanation is that they may have been analyzed suboptimally. Functional outcome is usually scored using ordinal scales (eg, modified Ranking Scale [mRS], Barthel Index) and yet analyses are often based on dichotomization of the data (eg, mRS 0 -2 versus 3-6), a process that usually results in a loss of statistical power. We are comparing a variety of ordinal and nominal statistical approaches using individual patient data from interventions which modify outcome (either positively or negatively) in acute stroke or *Indicates centers that are currently recruiting. stroke rehabilitation; neutral trial data from neutral interventions will not be included. The aim is to identify one (or more) optimal approach(es) for use in future stroke trials. Authors of relevant trials who are willing to share their trial data are invited to contact the investigators. 
Contact

PAIS: Paracetamol (Acetaminophen) In Stroke
A randomized, placebo-controlled, double-blind clinical trial. Subfebrile temperature and fever are strong predictors of poor functional outcome in acute stroke. Two pilot studies showed that high-dose paracetamol induces a decrease in body temperature of 0.3 to 0.4°C in patients with acute ischemic stroke, even if they are normothermic. This effect is noted within 4 hours after the start of treatment. The purpose of PAIS is to assess whether this decrease in body temperature translates into better clinical outcomes.
The study is designed as a multicenter, randomized, double-blind, placebo controlled trial. In total 2500 patients, with an acute ischemic or hemorrhagic stroke will be included. Treatment with high dose paracetamol (6 g/day) or placebo will be started within 12 hours after the onset of symptoms, and continued for 3 days. Exclusion criteria are body temperature Ͻ36°C or Ͼ39°C, a history of liver disease, alcohol abuse, liver enzymes increased Ͼ2ϫ the upper limit of normal, allergy to paracetamol and significant prestroke impairment (a score of Ͼ3 on the modified Rankin Scale). The study is very straightforward with limited data to be gathered. Follow-up at 3 months is done by telephone, by the central study office. The primary outcome measure is dichotomized Rankin Scale (0 to 2: good outcome, 3 to 6: poor outcome) at 3 months. Secondary endpoints are the score on the Barthel Index after 2 weeks, the EuroQol at 3 months, and body temperature after 24 hours of treatment. 
Prevention of Poststroke Depression After Acute Ischemic Stroke Using the Selective Serotonine Reuptake-Inhibitor Sertraline (PreDIS-Study)
The development of persistent depressive symptoms is a severe and frequent complication of ischemic stroke (ie, poststroke depression [PSD]). The reported prevalences of depressive symptoms in stroke patients varied from 20% to 50% and from 12% to 26% for major depressive symptoms in previous studies. Several follow-up studies revealed a higher overall mortality and a less beneficial functional outcome in stroke patients with major depression. Data from interventional studies treating or preventing PSD are rare. In most trials, tricyclic or tetracyclic antidepressive agents were used, which are often accompanied by therapy limiting adverse events, especially in elderly patients with cardiovascular disease. The PreDIS-Study was designed to limit such adverse events by the use of a selective serotonin reuptake inhibitor for which safety, tolerability, and efficacy has been shown in depressive patients with stroke or myocardial infarction. The primary endpoint of the study is to demonstrate a preventive effect of sertraline on the incidence of PSD. Secondary endpoints are improvement of functional outcome and quality of life. The PreDIS-Study is a double-blind, randomized, placebo-controlled trial that will enroll 300 patients from 10 neurological stroke units in Germany. Inclusion criterion is a unilateral ischemic cerebral infarction within 3 days prior to hospital admission. Major exclusion criteria are early and complete recovery of neurological symptoms, mechanical ventilation for more than 2 days, severe aphasia, dementia, preexisting antidepressive medication or depressive symptoms at study entry. Patients will be randomized to 50mg/d sertraline or placebo within the first 6 days after hospital admission. Depressive symptoms will be assessed using the Hospital Anxiety and Depression Scale, the Montgomery-Asberg Depression Scale, and the International Diagnosis Checklist for ICD-10 at baseline, 4 weeks, 12 weeks, and 24 weeks. Functional outcome will be determined by the European Stroke Scale, the modified Rankin Scale, and the Barthel Index. Cognitive performance will be assessed by the Mini-Mental State Examination and the Digit Span Test. Quality of life will be determined at 12 and 24 weeks using the SF-36. Treatment and follow-up are scheduled to continue for 6 months with follow-up visits after 4 weeks, 3 months, and 6 months. 
Safety of Tirofiban in Acute Ischemic Stroke (SaTIS)
The administration of highly selective glycoprotein IIb/IIIareceptor-antagonists has been shown to improve the treatment of acute coronary and experimental cerebral ischemia. Results of pilot studies in the setting of acute ischemic stroke with tirofiban, a nonpeptide antagonist with fast-acting and deactivating properties, led to the initiation of a multicenter, prospective, randomized, and placebo-controlled trial, targeting the frequency of cerebral hemorrhages as the primary endpoint. A total of 240 stroke patients with a symptom onset Ͼ22 hours and NIHSS score of 4 to 18, admitted outside the 3-to 6-hour time window, will receive either tirofiban or placebo, in addition to the centers' respective standard therapy. Study drug administration of tirofiban will be performed according to the concentration described in the PRISM-Plus study. A preliminary interim analysis will be due after inclusion of 30 patients per group. Patients' CCT-scans at the time of admission and 4 to 6 days after symptom onset will be subject to a central blinded evaluation. Secondary endpoint is the neurological outcome within 3 to 5 months after enrollment as judged by clinical disability scales: Barthel Index and modified Rankin Scale. The results of this study could be a rationale for a subsequent phase III study to examine the efficacy of tirofiban in acute ischemic stroke. 
Siblings With Ischemic Stroke Study (SWISS)
Cohort and twins studies suggest that there is an important genetic component to the overall risk of acquiring ischemic stroke. SWISS is a prospective, multicenter, clinical investigation to search for chromosomal regions of interest that harbor stroke susceptibility genes.
A microsatellite genome-wide screen will be carried out using DNA collected in this study from sibships consisting of a proband with ischemic stroke and 1 or more concordant sibling with or without discordant siblings. Three hundred concordant sibling pairs and 200 discordant siblings (800 total study subjects) will be enrolled. A genotype-blinded central committee adjudicates concordance and discordance for ischemic stroke in siblings. Probands are enrolled at participating clinical centers. Probands are potentially eligible for SWISS if they are diagnosed by a study neurologist as having had a CT-or MRI-confirmed ischemic stroke, have at least 1 living sibling with a history of stroke, and are at least 18 years old. Probands are excluded if the index stroke occurred within 48 hours after an invasive cerebrovascular or cardiovascular procedure or within 60 days after a nontraumatic subarachnoid hemorrhage. Also excluded are subjects with brain-biopsy-proven CNS vasculitis, mechanical aortic valve, mechanical mitral valve, bacterial endocarditis, CADASIL, Fabry's disease, homocystinuria, MELAS, or sickle cell disease. As of July 2005, 195 
Stent-protected Percutanous Angioplasty of the Carotid Versus Endarterectomy (SPACE)
SPACE is a multicenter, prospective, randomized trial to determine whether carotid endarterectomy (CEA) and percutaneous angioplasty (PTA) are equivalent with respect to ipsilateral stroke, a restenosis degree of Ն70% ECST criteria or Ն50% NASCET criteria, respectively, and technical success in patients with transient cerebral ischemia (TIA) or nondisabling stroke because of severe carotid stenosis. This study will include 950 patients per group. Interim analysis is planned after 450 patients per group have been treated or 3 years. Inclusion criterion is symptomatic, high-grade carotid stenosis (Ն70% ECST or Ն50% NASCET) within 180 days before randomization (TIA or nondisabling stroke). Primary endpoint is ipsilateral stroke or death within 30 days after intervention. Secondary endpoints are: Ipsilateral stroke or death within 24 months after randomization; restenosis Ն70% of treated carotid artery within 6, 12, and 24 months after randomization; technical complications (ME, vascular occlusion, residual stenosis Ն70%) within 6 and 30 days after intervention; stroke of any localization within 30 days and 24 months after intervention. Each study center consists of 3 departments (Neurology, Vascular Surgery, and Interventional Radiology). Certification for each of the 3 specialities has to be given by a quality standards committee, with documentation of 25 CEA per vascular surgeon, 25 PTA per interventional radiologist, and ultrasound expertise for neurologists. An external data monitoring strategy is in place. 
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
A number of large randomized trials have shown that statin treatment of patients with coronary heart disease (CHD) not only reduces the incidence of myocardial infarction (MI) and death, but also the occurrence of stroke. However, data on the effect of statins in the secondary prevention of stroke in patients with previous stroke or transient ischemic attack (TIA) are lacking. The SPARCL trial will evaluate the benefits of aggressive lipid lowering in this patient population by comparing the effects of atorvastatin versus placebo on specified cerebrovascular end points. The SPARCL study is a double-blind, randomized, placebo-controlled trial that enrolled Ͼ4200 patients from Ͼ200 centers worldwide. Inclusion criteria are previous stroke or TIA and low-density lipoprotein cholesterol Ͼ100 mg/dL (2.6 mmol/L) and Ͻ190 mg/dL (4.9 mmol/L). Patients with evidence of CHD will be excluded. Patients were randomized to 80 mg/d atorvastatin or placebo. The primary efficacy parameter is the time from randomization to the first occurrence of a primary end point, defined as a fatal or nonfatal stroke. Secondary efficacy parameters will include the occurrence of at least 1 primary end point, the time from randomization to the first occurrence of a secondary end point (cardiac death, nonfatal MI, resuscitated cardiac arrest, unstable angina), and the occurrence of at least 1 secondary end point. Treatment and follow-up is planned to be an average of 5 years. 
Study of Efficacy of Tirofiban in Acute Ischaemic Stroke (SETIS)
Study design: double-blind randomized trial of intravenous (IV) Tirofiban versus IV acetylsalicylic acid (ASA). Patients with acute ischaemic stroke presented within 6 hours will be randomized to treatment with Tirofiban (0.6 g/kg/min for 30 minutes followed by 0.15 g/kg/ min infusion for 72 hours) or ASA (300 mg IV daily bolus for 3 days), following a 1-way, matched pair, randomization list. Matching will be performed according to gender, age Յ70 or Ͼ70 years, NIHSS score Յ14 or Ͼ14. Treatment will be administered on a double-blind basis, using undistinguishable vials both for bolus infusion and continuous infusion. Serious adverse events will be reported to an unassociated physician of the safety committee. The choice of ASA and not placebo for the nontreatment group, is attributable to the evidence that early treatment with ASA has some beneficial effect, though limited, in short term mortality.
Study objectives: Assess the efficacy of Tirofiban in terms of short term neurological improvement (NIHSS score reduction of at least 4 points), and absence or minimal long term disability (NIHSS score and mRS score at 3 months decreased to 0 or 1).
Sample size: Sample size was based on an expected percentage of favourable outcomes on primary variables (short term neurological improvement and absence of long term disability) Ն15% in patients treated with Tirofiban than those treated with ASA, and considering in the latter treatment group a favourable outcome in at least 40% of the patients. Considering the short term primary variable, the total number of patients, increased by estimating a 10% total dropout rate, is 150 for each treatment group. Sample size computed on long term primary variables, under the same conditions, would require 120 patients for each treatment group, so that a series of 300 patients would be adequate for analysis of the protocol-specified primary variables. Variables will be analyzed on the basis of either the "intention-to-treat" or the "per-protocol" criteria. Prespecified causes of treatment withdrawal are intracranial haemorrhage, severe uncontrolled hypertension, allergic reactions, extracranial haemorrhage, and severe thrombocytopenia.
Patients: main inclusion criteria are the following: onset of symptoms within 6 hours, absence of haemorrhage at CT scan, absence of severe anemia, thrombocytopenia, major trauma or recent surgery, prolonged PT. 
Third International Stroke Trial (IST-3)
Background: for every 1000 patients with acute stroke treated with intravenous recombinant tissue-plasminogen activator (IV rtPA) within 6 hours of stroke onset, 55 avoid death or dependence, yet few patients are being treated worldwide. The third International Stroke Trial (IST-3) aims to provide more reliable evidence on which categories of patients benefit most from IV rtPA and how it could be more widely used.
Study design: IST-3 is an international, multicenter, randomised, controlled, post-licensing trial of IV rtPA (0.9 mg/kg) for acute ischaemic stroke, with a PROBE (Prospective, Randomised, Open, Blinded Endpoint) design.
Patient eligibility: eligible patients must be assessed and able to start treatment within 6 hours of onset, and a CT (or MR) scan must have excluded intracranial haemorrhage. Details of inclusion/exclusion criteria are given in the trial protocol.
Center eligibility: to join the study, centres must have an established acute stroke service which meets predefined criteria. Trial procedures are very efficient and aim to ensure trial treatment is started with minimal delay. Patient inclusion is by telephone call to a rapid centralized randomization system, which balances on key prognostic factors. Trial treatment is only allocated by the system after the baseline data have been successfully recorded and crosschecked. Brain imaging (CT or MR) must be repeated after treatment (at 24 to 48 hours). An international expert panel reviews 'blinded' all baseline and follow-up CT/MR images by means of an innovative centralised web-based image-reading system (see ACCESS study for details). In all centres, follow-up is conducted by centralized (blinded) postal or telephone questionnaire, conducted independently of the clinician treating the patient.
Trial outcome measures: the primary measure of outcome is death or dependence at 6 months (poor functional outcome). A number of secondary outcomes are specified in the protocol. Planned subgroup analyses will include an assessment of the effect of: age, stroke severity, time to randomization, CT appearances, blood pressure and other factors on the risks and benefits of treatment. 
The United Kingdom Glucose Insulin in Stroke Trial (GIST-UK)
There is an increasing evidence from both animal and clinical studies that diabetes and/or hyperglycemia following stroke is associated with an adverse prognosis, although this association has never been confirmed in any clinical trial. In addition, although treatment of hyperglycemia with insulin is increasingly undertaken as part of acute stroke care, the risks and benefits have never been formally explored in a randomized controlled trial. The safety and practicability of glucose/ potassium/insulin (GKI) infusions to maintain euglycemia after stroke has previously been demonstrated in the GIST study. GIST-UK seeks to determine, by means of a multicenter-randomized trial, whether outcome from acute stroke can be favorably influenced by GKI-induced and -maintained euglycemia.Patients presenting with CT-proven acute stroke within 24 hours of onset and admission plasma glucose of Ͼ6.0 mmol/L and Ͻ17.0 mmol/L are eligible. The primary end points are all-cause mortality and the proportion of patients with a poor outcome (modified Rankin score 4 to 6) at 90 days. Principal Investigator: Prof C.S. Gray Contact: Prof. C.S. Gray, Newcastle University, Department of Geriatrics, Sunderland Royal Hospital, Kayll Road, Sunderland SR4 7T9, UK. Phone 44-191-565-6256, ext 41245. Fax 44-191-569-9767 
VITAmins TO Prevent Stroke (VITATOPS)
The VITATOPS study is a multicenter, randomized, double blind, placebo-controlled secondary stroke prevention trial to determine whether the addition of vitamin supplements (B 12 500 g; B 6 25 mg; Folate 2 mg) to best medical/surgical management (including modification of risk factors) will reduce the combined incidence of recurrent vascular events (stroke, myocardial infarction) and vascular death in patients with recent stroke or transient ischaemic attack (TIA). All patients presenting to one of the participating neurologists or general physicians within seven months of stroke (ischaemic or hemorrhagic) or TIA (eye or brain) are eligible for this trial. Eligible patients will be randomized in a double-blind fashion to receive multivitamins or placebo, 1 tablet daily. The primary outcome event is the composite event "stroke, myocardial infarction, or death from any vascular cause," whichever occurs first. Our target is to recruit a total of 8000 patients over the next two years with a median follow-up of 2.5 years. Recruitment to the trial began in November 1998 and is planned to continue until mid 2007. We aim to complete final follow-up by mid 2008. However, the Steering Committee will be flexible in dictating the need for ongoing recruitment and continuing follow-up, depending on the overall rate of the primary outcome event in the entire cohort at each interim analysis. 
